Neuropharmacological profile of a novel potential atypical antipsychotic drug Y-931 (8-fluoro-12-(4-methylpiperazin-1-yl)- 6H-[1]benzothieno[2,3-b][1,5] benzodiazepine maleate)

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Toshihiko MorimotoKeiji Yamagami

Abstract

The neuropharmacological profile of Y-931, 8-fluoro-12- (4-methylpiperazin-1-yl)- 6H-[1]benzothieno [2,3-b][1,5]benzodiazepine maleate, was investigated in comparison with those of typical and claimed atypical antipsychotic drugs. Similar to clozapine and olanzapine, Y-931 interacted with multiple neurotransmitter receptors such as dopaminergic, serotonergic, alpha-adrenergic, muscarinic and histaminergic receptors. Y-931, as well as the other antipsychotics, was active in a dose-dependent manner in established tests which are indicative of potential antipsychotic activity such as inhibition of apomorphine-induced hyperactivity and suppression of conditioned avoidance responses, however, only Y-931 and clozapine were devoid of cataleptogenic potential. In models of N-methyl-D-aspartate (NMDA) receptor hypofunction, Y-931 demonstrated the most potent protective action against the dizocilpine-induced neurotoxicity (neuronal vacuolization) in the rat retrosplenial cortex ([Y-931 (ED(50); 0.20 mg/kg, p.o.), olanzapine (1.1), clozapine (5.7), risperidone (6.9), haloperidol (19)). Furthermore, Y-931 and clozapine, unlike the other antipsychotics used, reversed the dizocilpine-induced social deficits at the same doses at which their n...Continue Reading

Citations

May 26, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Johan P RungMaria L Carlsson
Feb 24, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Kenji HashimotoMasaomi Iyo
Jan 18, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Lin ZhangKenji Hashimoto
Jun 5, 2002·Chemical & Pharmaceutical Bulletin·Toshiyuki KoharaMasafumi Arita
Dec 21, 2005·Proceedings of the National Academy of Sciences of the United States of America·Noboru HiroiSoh Agatsuma
Apr 27, 2010·Pharmacology, Biochemistry, and Behavior·C L Danna, G I Elmer
Jul 23, 2013·Neurochemistry International·Fukie Niijima-YaoitaKoichi Tan-No
Apr 23, 2004·Expert Opinion on Investigational Drugs·Ann M Mortimer
Apr 5, 2011·Behavioural Brain Research·Anand GururajanDaniel Thomas Malone
Dec 4, 2003·Journal of Pharmacological Sciences·Yasuyuki ShiigiDaniel E Casey
Nov 7, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Naoe OkamuraMasaomi Iyo
Aug 17, 2021·Journal of Clinical Pharmacology·James R Docherty, Hadeel A Alsufyani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Anti-N-Methyl-D-Aspartate Receptor Encephalitis

Anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis is a form of of brain inflammation due to antibodies against NMDA receptors. Discover the latest research on anti-NMDA receptor encephalitis here.

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here